Kelly Kilpatrick

SVP, Head of US Commercial – Ocular Gene Therapy
Spark Therapeutics

Kelly Kilpatrick brings over 30 years of commercial experience in the pharmaceutical and biotech industries.

High-Cost Drug Therapies: The Intersection of Cost & Patient Access
Tuesday, June 13, 2023
12:30 – 1:30 p.m. CT

Kelly Kilpatrick brings over 30 years of commercial experience in the pharmaceutical and biotech industries. Kelly joined Spark Therapeutics in 2017 and she currently leads all aspects of Spark Therapeutics US Commercial business for ocular gene therapy. Kelly contributed to the commercial launch of the first gene therapy approved by the FDA for genetic disease, specifically inherited retinal disease. Kelly also played an integral role in the launch of the SPARK PATHSM, an innovative payment model in support of LUXTURNA™, which aims to advance access for eligible patients, while balancing the needs of all stakeholders involved in the care delivery continuum.

Before joining Spark, Kelly led the market access team for ophthalmology at Regeneron. Previously, she held roles of increasing responsibility within the commercial organization at GSK during her 20-year tenure, including market access and leadership positions. Kelly holds a Bachelor of Science in Biochemistry from the Rochester Institute of Technology. She currently resides in the Philadelphia-area with her family.

Kelly holds a Bachelor of Science in Biochemistry from the Rochester Institute of Technology.

EDUCATION

Learn more about our Crossroads 2023 Speakers!

Peter D’Alba

Aurelia Chaudhury

Edna Y. Marín Ramos

Sandy Kapur

Jenn McNary

ALL SPEAKERS

The South Carolina Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Continuing education credits will be available to participants who fully attend the program and then complete an online educational activity evaluation. A unique code given at each activity must be provided in the evaluation to receive credit. Grievances regarding the education program must be submitted in writing to the SCPhA ACPE Administrator immediately following the program.